Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.

Vitte J, Traver S, Maués De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A.

J Neuropathol Exp Neurol. 2010 Sep;69(9):959-72. doi: 10.1097/NEN.0b013e3181efc01c.

PMID:
20720502
[PubMed - indexed for MEDLINE]
2.

LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.

Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.

Neuropathol Appl Neurobiol. 2011 Dec;37(7):777-90. doi: 10.1111/j.1365-2990.2011.01187.x.

PMID:
21696411
[PubMed - indexed for MEDLINE]
3.

LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.

Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R.

Neuropathol Appl Neurobiol. 2008 Jun;34(3):272-83. Epub 2007 Oct 26.

PMID:
17971075
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.

Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, Waldvogel HJ, Arai H, Dawson TM, Moore DJ, Emson PC.

Brain Res. 2007 Jun 25;1155:208-19. Epub 2007 Apr 19.

PMID:
17512502
[PubMed - indexed for MEDLINE]
5.

G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Gaig C, Martí MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E.

J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. Epub 2007 Jan 8.

PMID:
17210620
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.

Higashi S, Moore DJ, Yamamoto R, Minegishi M, Sato K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Hino H, Kosaka K, Emson PC, Wada K, Dawson VL, Dawson TM, Arai H, Iseki E.

J Neuropathol Exp Neurol. 2009 Sep;68(9):994-1005. doi: 10.1097/NEN.0b013e3181b44ed8.

PMID:
19680143
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.

Giordana MT, D'Agostino C, Albani G, Mauro A, Di Fonzo A, Antonini A, Bonifati V.

Mov Disord. 2007 Jan 15;22(2):275-8.

PMID:
17149743
[PubMed - indexed for MEDLINE]
8.
9.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

PMID:
21238487
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

LRRK2 and neurodegeneration.

Santpere G, Ferrer I.

Acta Neuropathol. 2009 Mar;117(3):227-46. doi: 10.1007/s00401-008-0478-8. Epub 2009 Jan 14. Review.

PMID:
19142648
[PubMed - indexed for MEDLINE]
11.

A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.

Dusonchet J, Kochubey O, Stafa K, Young SM Jr, Zufferey R, Moore DJ, Schneider BL, Aebischer P.

J Neurosci. 2011 Jan 19;31(3):907-12. doi: 10.1523/JNEUROSCI.5092-10.2011.

PMID:
21248115
[PubMed - indexed for MEDLINE]
Free Article
12.

Biochemical and pathological characterization of Lrrk2.

Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM.

Ann Neurol. 2006 Feb;59(2):315-22.

PMID:
16437584
[PubMed - indexed for MEDLINE]
13.

Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.

Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG.

Int J Biol Sci. 2011;7(6):753-61. Epub 2011 Jun 9.

PMID:
21698001
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Anatomical localization of leucine-rich repeat kinase 2 in mouse brain.

Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M.

Neuroscience. 2006;139(3):791-4. Epub 2006 Feb 28.

PMID:
16504409
[PubMed - indexed for MEDLINE]
15.

Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.

Mamais A, Raja M, Manzoni C, Dihanich S, Lees A, Moore D, Lewis PA, Bandopadhyay R.

Neurobiol Dis. 2013 Oct;58:183-90. doi: 10.1016/j.nbd.2013.05.017. Epub 2013 Jun 5.

PMID:
23747310
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL.

Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42. Epub 2012 Apr 27.

PMID:
22539006
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.

Guerreiro PS, Huang Y, Gysbers A, Cheng D, Gai WP, Outeiro TF, Halliday GM.

J Mol Med (Berl). 2013 Apr;91(4):513-22. doi: 10.1007/s00109-012-0984-y. Epub 2012 Nov 27.

PMID:
23183827
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
[PubMed - indexed for MEDLINE]
19.

Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.

Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS.

Am J Pathol. 2002 May;160(5):1655-67.

PMID:
12000718
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.

Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G, Lees A, Houlden H, Revesz T.

Neurobiol Aging. 2013 Dec;34(12):2889.e5-9. doi: 10.1016/j.neurobiolaging.2013.04.011. Epub 2013 May 9. Review.

PMID:
23664753
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk